Increased plasma transforming growth factor-β1 in migraine

Headache

Volumn 45, Issue 9, 2005, Pages 1224-1228

  Ishizaki, Kumiko ^a   Takeshima, Takao ^a   Fukuhara, Yoko ^a   Araki, Haruko ^a   Nakaso, Kazuhiro ^a   Kusumi, Masayoshi ^a   Nakashima, Kenji ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Comorbidity; Cytokine; Neurogenic inflammation

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1; TGFB1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE FREE INTERVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; EPISODIC TENSION HEADACHE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; PAIN ASSESSMENT; PAIN THRESHOLD; POST HOC ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SAMPLE SIZE; THROMBOCYTE POOR PLASMA; ANALYSIS OF VARIANCE; BLOOD; COMPARATIVE STUDY; TENSION HEADACHE;

ADULT; ANALYSIS OF VARIANCE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIGRAINE DISORDERS; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; TENSION-TYPE HEADACHE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 33644878471     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2005.00246.x     Document Type: Article

References (27)

1. Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain. 2000;123(Pt 8):1703-1709.
2. Welch KMA, Barkley GL, Tepley N, et al. Central neurogenic mechanisms of migraine. Neurology. 1993;43(suppl 3):S21-S25.
3. Moskowitz MA, Macfarlane R. Neurovascular and molecular mechanisms in migraine headaches. Cerebrovasc Brain Metab Rev. 1993;5:159-177.
4. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993;33:48-56.
5. Mediana JL, Diamond S. Migraine and atopy. Headache. 1976;15(4):271-273.
6. Monro J, Carini C, Brostoff J. Migraine is a food-allergic disease. Lancet. 1984;2(8405):719-721.
7. Munno I, Marinaro M, Bassi A, et al. Immunological aspects in migraine: increase of IL-10 plasma levels during attack. Headache. 2001;41(8):764-767.
8. Terwindt GM, Ferrari MD, Tijhuis M, et al. The impact of migraine on quality of life in the general population: the GEM study. Neurology. 2000;55(5):624-629.
9. Clark DA, Coker R. Transforming growth factor-beta (TGF-beta). Int J Biochem Cell Biol. 1998;30(3):293-298.
10. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(suppl 7):1-96.
11. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders; 2nd Edition. Cephalalgia. 2004;24(suppl 1):1-160.
12. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol. 1998;16:137-161.
13. D'Andrea G, Cananzi AR, Perini F, et al. Platelet models and their possible usefulness in the study of migraine pathogenesis. Cephalalgia. 1995;15(4):265-271.
14. Kemper RH, Meijler WJ, Korf J, et al. Migraine and function of the immune system: a meta-analysis of clinical literature published between 1966 and 1999. Cephalalgia. 2001;21(5):549-557.
15. Tietjen G, Dore-Duffy P, Beaumont T, Athanas K, Welch KMA. Ictal increases in vascular endothelial growth factor, and transforming growth factor beta 1 in young women with migraine [Abstract]. Headache. 1999;39(5):383.
16. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000;342(18):1350-1358.
17. Marek A, Brodzicki J, Liberek A, et al. TGF-beta (transforming growth factor-beta) in chronic inflammatory conditions - a new diagnostic and prognostic marker? Med Sci Monk. 2002;8(7):RA145-RA151.
18. Kong FM, Anscher MS, Murase T, et al. Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg. 1995;222(2):155-162.
19. Rollnik JD, Sindern E, Schweppe C, et al. Biologically active TGF-beta 1 is increased in cerebrospinal fluid while it is reduced in serum in multiple sclerosis patients. Acta Neurol Scand. 1997;96(2):101-105.
20. Flood-Page P, Menzies-Gow A, Phipps S, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest. 2003;112(7):1029-1036.
21. Grainger DJ, Wakefield L, Bethell HW, et al. Release and activation of platelet latent TGF-beta in blood clots during dissolution with plasmin. Nat Med. 1995;1(9):932-937.
22. Assoian RK, Komoriya A, Meyers CA, et al. Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem. 1983;258(11):7155-7160.
23. Ashcroft GS. Bidirectional regulation of macrophage function by TGF-beta. Microbes Infect. 1999;1(15):1275-1282.
24. Inoue K, Yamazaki H, Manabe Y, et al. Release of a substance that suppresses spontaneous motor activity in the brain by physical exercise. Physiol Behav. 1998;64(2):185-190.
25. Inoue K, Yamazaki H, Manabe Y, et al. Transforming growth factor-beta activated during exercise in brain depresses spontaneous motor activity of animals. Relevance to central fatigue. Brain Res. 1999;846(2):145-153.
26. Cohen MM Jr. TGF beta/Smad signaling system and its pathologic correlates. Am J Med Genet. 2003;116A(1):1-10.
27. Kondo S, Isobe K, Ishiguro N, et al. Transforming growth factor-beta 1 enhances the generation of allospecific cytotoxic T lymphocytes. Immunology. 1993;79(3):459-464.